Four pharmacy trends every business leader should be watching | Coverage & Care

For business leaders trying to manage healthcare costs, the pharmacy component has become a strategic priority.

The prescription drug market is evolving rapidly, shaped by a dual force: breakthrough innovation and intensifying regulatory scrutiny. Together, these dynamics are reshaping how pharmacy benefits are priced, structured, and experienced—not just for health plans, but for employers, their advisors, and for the employees they support.

Amid this complexity, one principle remains essential: disciplined stewardship of healthcare dollars. Organizations that stay focused on clinical value and total cost will be best positioned to navigate what comes next, particularly when working through a health plan or pharmacy benefit partner.

Here are four pharmacy trends business leaders should be watching closely in order to offer optimal pharmacy benefits to their employees.

1. Policy pressure is accelerating a shift toward transparency and value

Legislative and regulatory momentum is building across the pharmacy landscape. Federal actions like provisions in the Inflation Reduction Act, combined with state and federal discussions around pharmacy benefit manager (PBM) reform, are placing new pressure on pharmaceutical manufacturers and the broader supply chain.

The intent is clear: increase pricing transparency and ensure greater value for every dollar spent.

These efforts are prompting a re-examination of long-standing practices, from how drugs are priced to how intermediaries operate. For employers—whether fully insured or self-funded—this means the rules governing pharmacy benefits are not static. They are evolving in real time, with implications for pricing structures, contract models, and financial predictability within your health plan arrangements.

Business leaders should expect continued disruption as policymakers push toward a system that prioritizes clarity and accountability—and should engage their health plan partners to understand how these changes are being operationalized.

2. The economics of drug pricing are quietly changing

One of the most important shifts underway is how drugs are priced.

Historically, the system has relied heavily on high list prices (wholesale acquisition cost, or WAC) paired with significant manufacturer rebates. Today, that model is beginning to change.

A growing number of manufacturers are reducing list prices while simultaneously reducing or eliminating rebates. The goal is to lower out-of-pocket costs for members at the pharmacy counter. This is a welcome change for consumers, but one that fundamentally alters pharmacy benefit economics.

For employers, this trend reinforces the need to look beyond traditional performance guarantees or rebate levels when evaluating a pharmacy program. Whether you are self-funded and directly exposed to claims costs, or fully insured and managing premium trends, the focus must shift to net cost, member affordability, and total cost of care.

In short, what looks less expensive on paper may not behave the same way financially. Understanding how your health plan evaluates and manages these tradeoffs is critical—particularly for the employees you support.

3. Specialty and biosimilar competition is redefining the cost curve

While policy and pricing models evolve, one trend continues to dominate pharmacy spend: specialty drugs.

These therapies, which are often used to treat complex or chronic conditions, remain the fastest-growing and most expensive segment of the market. Managing their cost trajectory is one of the biggest challenges facing employers today. It’s also a key driver of both claim volatility in self-funded plans and premium increases in fully insured arrangements.

Innovation improves outcomes and creates new opportunities for cost management.

Biosimilars, highly effective alternatives to existing biologic drugs, are expanding rapidly and introducing meaningful competition into the marketplace. Early adopters have demonstrated that it is possible to bend the cost curve while maintaining high-quality outcomes. In fact, Excellus BlueCross BlueShield (BCBS) has advocated for the use of biosimilars since 2018, when it was the first standalone health insurer in the U.S. to offer a biosimilar in a major drug category.

This is not just about cost savings. It reflects a broader shift toward decision-making grounded in long-term value rather than short-term financial incentives.

For business leaders, the takeaway is clear: pharmacy strategies that actively manage specialty utilization and embrace biosimilar innovation and adoption—often in partnership with your health plan—can make a measurable difference in total healthcare spend.

4. The pharmacy supply chain Is undergoing structural change

Beyond individual drugs or policies, the broader pharmacy ecosystem itself is being reshaped.

Competitive pressures, combined with regulatory scrutiny, are driving changes in how value is generated and distributed across the supply chain. PBM reform efforts—particularly those focused on transparency, pass-through pricing models, and the reevaluation of legacy revenue streams—are accelerating this transformation.

At the same time, many of the dynamics long anticipated in the market are now converging: greater scrutiny of rebates, increased demand for transparency, and a shift toward lower upfront pricing.

The result is a recalibration of pharmacy finance models.

For employers, this means more variability as well as more opportunity to better align pharmacy strategies with organizational goals. It also makes the role of your health plan or PBM partner more important than ever, as benefit structures that once seemed standard are being reconsidered.

What this means for business leaders

Taken together, these trends point to a fundamental shift. Pharmacy is moving from a rebate-driven, high-list-price model toward a system that emphasizes transparency, upfront affordability, and measurable value.

That’s good news for members. But it introduces new complexity for employers.

Success in this environment depends on asking better questions and asking them of the right partners:

• Are we focused on total cost, not just individual components like rebates?
• Do our pharmacy strategies prioritize long-term value over short-term savings?
• How is our health plan managing emerging therapies, pricing changes, and regulatory shifts on our behalf?
• Are we aligned with partners who can adapt to changing market dynamics?

Organizations that take a disciplined, informed approach, grounded in clinical effectiveness and responsible cost management, will be best positioned to navigate these changes.

Paul Valley is Senior Vice President, Commercial Group Markets, Excellus BlueCross BlueShield.